Third Harmonic Bio (THRD) Q3 2024 earnings summary

Executive summary

• Third Harmonic Bio is focused on developing oral KIT inhibitors for inflammatory diseases, with lead candidate THB335 in Phase 1 trials and expansion plans for other mast cell-mediated disorders.

• THB335 Phase 1 SAD/MAD clinical trial is progressing, with results expected in Q1 2025 and Phase 2 preparations underway for chronic spontaneous urticaria.

• The company reported a net loss of $13.8 million for Q3 2024 and $32.4 million for the nine months ended September 30, 2024, reflecting increased R&D and G&A expenses.

• Cash and cash equivalents totaled $296.1 million as of September 30, 2024, expected to fund operations through at least 2026.

• The company continues to operate at a loss and does not expect product revenue for several years, relying on equity offerings and other capital sources.

Financial highlights

• Q3 2024 net loss was $13.8 million, up from $7.3 million in Q3 2023; nine-month net loss was $32.4 million, up from $24.0 million year-over-year.

• R&D expenses rose to $11.3 million for Q3 2024, mainly due to THB335 program and higher personnel costs.

• G&A expenses increased to $5.7 million for Q3 2024, primarily due to higher personnel and executive recruiting costs.

• Cash used in operating activities was $23.3 million for the nine months ended September 30, 2024; net cash provided by financing activities was $50.3 million, primarily from the equity offering.

• Interest income for the nine months ended September 30, 2024, was $10.1 million, reflecting higher cash balances and interest rates.

Outlook and guidance

• Cash and cash equivalents are expected to fund operations and capital expenses through at least 2026, but additional funding may be needed depending on development progress and market conditions.

• Phase 1 clinical results for THB335 are expected in Q1 2025, with a Phase 2 trial in CSU and expansion into additional indications planned.

• The company anticipates continued increases in R&D and G&A expenses as it advances clinical programs and expands operations.